Sclerostin is essential for alveolar bone loss in occlusal hypofunction

Xu,Yang; Wang,Lufei; Sun,Yao; Han,Xianglong; Gao,Tian; Xu,Xin; Chen,Tian; Zhao,Xuefeng; Zeng,Huan; Wang,Yanmin; Bai,Ding

doi:10.3892/etm.2016.3124

Sclerostin is essential for alveolar bone loss in occlusal hypofunction

Authors:
- Yang Xu
- Lufei Wang
- Yao Sun
- Xianglong Han
- Tian Gao
- Xin Xu
- Tian Chen
- Xuefeng Zhao
- Huan Zeng
- Yanmin Wang
- Ding Bai
View Affiliations

Affiliations: Department of Orthodontics, State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Oral Implantology, Dental Transformation Medical Center, College of Stomatology, Tongji University, Shanghai 200011, P.R. China, Department of Obstetrics and Gynecology, Transformation Medical Center, Tongji University, Shanghai 200011, P.R. China
Published online on: March 2, 2016 https://doi.org/10.3892/etm.2016.3124
Pages: 1812-1818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone loss is caused by occlusal hypofunction and is a serious health concern. This is particularly true of tooth loss, which is common in the elderly. However, the cellular and molecular mechanisms underlying bone loss have yet to be fully elucidated. Sclerostin and Wnt/β‑catenin signaling have previously been reported to serve important roles in regulating bone remodeling. Therefore, the present study aimed to investigate the involvement of sclerostin and Wnt/β‑catenin signaling in occlusal hypofunction‑induced alveolar bone remodeling. The unilateral maxillary molars of 14 male Sprague‑Dawley rats were extracted in order to establish a model of occlusal hypofunction. For each rat, the non‑extraction side was treated as the control group for comparisons with the extraction side. At 8 weeks after tooth extraction, the rats were sacrificed and alveolar bone specimens were harvested for X‑ray radiography, micro‑computed tomography (CT) and histological and immunohistochemical examinations. Bone loss and architecture deterioration were observed at the occlusal hypofunction side. The bone mineral density was markedly decreased and the ratio of bone volume to total volume was significantly decreased at the hypofunction side, as compared with the control side (P<0.001). In addition, the number of osteoclasts at the hypofunction side were significantly increased compared with that in the control side (P<0.001), as demonstrated using tartrate‑resistant acid phosphatase staining. Furthermore, the protein expression levels of sclerostin and receptor activator of nuclear factor‑κB ligand were increased, whereas those of β‑catenin were decreased, at the hypofunction side when compared with the control side. In conclusion, the results of the present study suggested that occlusal hypofunction‑induced bone loss may be associated with upregulated expression of sclerostin, which, in turn, may inhibit the activity of the Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Recent advances in oral health. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 826:1–37. 1992.PubMed/NCBI
2	Müller F, Naharro M and Carlsson GE: What are the prevalence and incidence of tooth loss in the adult and elderly population in Europe? Clin Oral Implants Res. 18(Suppl 3): S2–S14. 2007. View Article : Google Scholar
3	Harada S and Rodan G: Control of osteoblast function and regulation of bone mass. Nature. 423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
4	Jacobs CR, Temiyasathit S and Castillo AB: Osteocyte mechanobiology and pericellular mechanics. Annu Rev Biomed Eng. 12:369–400. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bikle DD and Halloran BP: The response of bone to unloading. J Bone Miner Metab. 17:233–244. 1999. View Article : Google Scholar : PubMed/NCBI
6	Shimomoto Y, Chung CJ, Iwasaki HY, Muramoto T and Soma K: Effects of occlusal stimuli on alveolar/jaw bone formation. J Dent Res. 86:47–51. 2007. View Article : Google Scholar : PubMed/NCBI
7	von Wowern N, Hjørting-Hansen E and Stoltze K: Changes in bone mass in rat mandibles after tooth extraction. Int J Oral Surg. 8:229–233. 1979. View Article : Google Scholar : PubMed/NCBI
8	Ejiri S, Toyooka E, Tanaka M, Anwar RB and Kohno S: Histological and histomorphometrical changes in rat alveolar bone following antagonistic tooth extraction and/or ovariectomy. Arch Oral Biol. 51:941–950. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kuroda S, Mukohyama H, Kondo H, Aoki K, Ohya K, Ohyama T and Kasugai S: Bone mineral density of the mandible in ovariectomized rats: Analyses using dual energy X-ray absorptiometry and peripheral quantitative computed tomography. Oral Dis. 9:24–28. 2003. View Article : Google Scholar : PubMed/NCBI
10	Elovic RP, Hipp JA and Hayes WC: Maxillary molar extraction decreases stiffness of the mandible in ovariectomized rats. J Dent Res. 73:1735–1741. 1994.PubMed/NCBI
11	Elovic RP, Hipp JA and Hayes WC: Maxillary molar extraction causes increased bone loss in the mandible of ovariectomized rats. J Bone Miner Res. 10:1087–1093. 1995. View Article : Google Scholar : PubMed/NCBI
12	Glass DA II and Karsenty G: Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol. 73:43–84. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S and Ikeda K: Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5:464–475. 2007. View Article : Google Scholar : PubMed/NCBI
14	Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H and Mueller TD: NMR structure of the Wnt modulator protein sclerostin. Biochem Biophys Res Commun. 380:160–165. 2009. View Article : Google Scholar : PubMed/NCBI
15	Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW and Reeve J: Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19:1842–1844. 2005.PubMed/NCBI
16	Bonewald LF and Johnson M: Osteocytes, mechanosensing and Wnt signaling. Bone. 42:606–615. 2008. View Article : Google Scholar : PubMed/NCBI
17	Galli C, Passeri G and Macaluso GM: Osteocytes and WNT: The mechanical control of bone formation. J Dent Res. 89:331–343. 2010. View Article : Google Scholar : PubMed/NCBI
18	Paszty C, Turner CH and Robinson MK: Sclerostin: A gem from the genome leads to bone-building antibodies. J Bone Miner Res. 25:1897–1904. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM and Atkins GJ: Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 6:e259002011. View Article : Google Scholar : PubMed/NCBI
20	Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X and He L: Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 24:1651–1661. 2009. View Article : Google Scholar : PubMed/NCBI
21	Naveh GR, Lev-Tov CN, Zaslansky P, Shahar R and Weiner S: Tooth-PDL-bone complex: Response to compressive loads encountered during mastication-a review. Arch Oral Biol. 57:1575–1584. 2012. View Article : Google Scholar : PubMed/NCBI
22	Gerritsen AE, Allen PF, Witter DJ, Bronkhorst EM and Creugers NH: Tooth loss and oral health-related quality of life: A systematic review and meta-analysis. Health Qual Life Outcomes. 8:1262010. View Article : Google Scholar : PubMed/NCBI
23	Schropp L, Wenzel A, Kostopoulos L and Karring T: Bone healing and soft tissue contour changes following single-tooth extraction: A clinical and radiographic 12-month prospective study. Int J Periodontics Restorative Dent. 23:313–323. 2003.PubMed/NCBI
24	Tan WL, Wong TL, Wong MC and Lang NP: A systematic review of post-extractional alveolar hard and soft tissue dimensional changes in humans. Clin Oral Implants Res. 23(Suppl 5): S1–S21. 2012. View Article : Google Scholar
25	Sennerby L, Carsson GE, Bergman B and Warfvinge J: Mandibular bone resorption in patients treated with tissue-integrated prostheses and in complete-denture wearers. Acta Odontol Scand. 46:135–140. 1988. View Article : Google Scholar : PubMed/NCBI
26	Bodic F, Hamel L, Lerouxel E, Baslé MF and Chappard D: Bone loss and teeth. Joint Bone Spine. 72:215–221. 2005. View Article : Google Scholar : PubMed/NCBI
27	Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A and Weinbaum S: Mechanosensation and transduction in osteocytes. Bone. 54:182–190. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bonewald LF: The amazing osteocyte. J Bone Miner Res. 26:229–238. 2011. View Article : Google Scholar : PubMed/NCBI
29	Bonewald LF: Mechanosensation and transduction in osteocytes. Bonekey Osteovision. 3:7–15. 2006. View Article : Google Scholar : PubMed/NCBI
30	Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE and Turner CH: Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem. 283:5866–5875. 2008. View Article : Google Scholar : PubMed/NCBI
31	Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S and Krumlauf R: Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 21:1738–1749. 2006. View Article : Google Scholar : PubMed/NCBI
32	Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI and Bellido T: Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 50:209–217. 2012. View Article : Google Scholar : PubMed/NCBI
33	Lewiecki EM: Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 6:48–57. 2014. View Article : Google Scholar : PubMed/NCBI
34	Virdi AS, Irish J, Sena K, Liu M, Ke HZ, McNulty MA and Sumner DR: Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis. J Bone Joint Surg Am. 97:133–40. 2015. View Article : Google Scholar : PubMed/NCBI
35	Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, Gattone VH 2nd and Allen MR: Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 30:499–509. 2015. View Article : Google Scholar : PubMed/NCBI
36	Costa AG, Bilezikian JP and Lewiecki EM: The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. Curr Opin Nephrol Hypertens. 24:324–329. 2015.PubMed/NCBI
37	Tanaka Y, Nakayamada S and Okada Y: Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 4:325–328. 2005. View Article : Google Scholar : PubMed/NCBI
38	Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, et al: Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 17:1231–1234. 2011. View Article : Google Scholar : PubMed/NCBI
39	Semënov M, Tamai K and He X: SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 280:26770–26775. 2005. View Article : Google Scholar : PubMed/NCBI
40	Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE and Wu D: Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 280:19883–19887. 2005. View Article : Google Scholar : PubMed/NCBI
41	Muramoto T, Takano Y and Soma K: Time-related changes in periodontal mechanoreceptors in rat molars after the loss of occlusal stimuli. Arch Histol Cytol. 63:369–380. 2000. View Article : Google Scholar : PubMed/NCBI
42	Lekic P and McCulloch CA: Periodontal ligament cell population: The central role of fibroblasts in creating a unique tissue. Anat Rec. 245:327–341. 1996. View Article : Google Scholar : PubMed/NCBI
43	Ke HZ, Richards WG, Li X and Ominsky MS: Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 33:747–783. 2012. View Article : Google Scholar : PubMed/NCBI
44	Shahnazari M, Wronski T, Chu V, Williams A, Leeper A, Stolina M, Ke HZ and Halloran B: Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Calcif Tissue Int. 91:50–58. 2012. View Article : Google Scholar : PubMed/NCBI
45	Spatz JM, Ellman R, Cloutier AM, Louis L, van Vliet M, Suva LJ, Dwyer D, Stolina M, Ke HZ and Bouxsein ML: Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 28:865–874. 2013. View Article : Google Scholar : PubMed/NCBI